When was 1nhaler founded?

1nhaler was founded in 2017 and raised its 1st funding round 2 years after it was founded.

Where is 1nhaler located?

1nhaler is headquartered in Edinburgh, United Kingdom.

Who is the current CEO of 1nhaler?

Lisa McMyn of 1nhaler. They have also founded 1 company.

How many employees does 1nhaler have?

As of May 31, 2026, the latest employee count at 1nhaler is 6.

Is 1nhaler a funded company?

1nhaler is a funded company, having raised a total of $4.74M across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Apr 14, 2019.

When was the latest funding round of 1nhaler?

1nhaler's latest funding was a $***** Seed round on Nov 17, 2025, with participation from 3 investors. Its primary sector is Drug Delivery. Globally, the Drug Delivery sector has seen $511M in funding in 2026 to date.

Where does 1nhaler rank among its competitors?

1nhaler ranks 13th amongst 109 active competitors, of which 27 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was Nebu~Flow, which secured $2.69M in Jun, 2026.

Who are the top competitors of 1nhaler?

1nhaler's top competitors include MannKind Corp, Impel NeuroPharma and Beyond Air. Among them, Nebu~Flow secured the most recent funding round in June, 2026.

1nhaler - 2026 Company Profile, Team, Funding & Competitors

1nhaler is a seed company based in Edinburgh (United Kingdom), founded in 2017 by Don Smith and Lisa McMyn. It operates as a Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons. 1nhaler has raised $4.74M in funding from Archangels. The company has 109 active competitors, including 27 funded and 20 that have exited. Its top competitors include companies like MannKind Corp, Impel NeuroPharma and Beyond Air.

Company Details

Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons. It offers a portable inhaler made from cardboard and it folds from a flat, credit‑card shape into a 3D inhaler activated by a single breath. The lead project is salbutamol for asthma relief.

Key Metrics

Founded Year

2017

Location

Edinburgh, United Kingdom

Stage

Seed

Total Funding

$4.74M in 4 rounds

Latest Funding Round

Seed, Nov 17, 2025, $*****

Investors

Archangels & 4 more

Ranked

13^th among 109 active competitors

Employee Count

6 as on May 31, 2026

Similar Companies

MannKind Corp & 126 more

View 1nhaler's full profile

1nhaler has raised a total funding of $4.74M over 4 rounds. Its first funding round was on Apr 14, 2019. Its latest funding round was a Seed round on Nov 17, 2025 for $*****. 3 investors participated in its latest round. 1nhaler has 4 institutional investors and 1 angel investor.

Here is the list of recent funding rounds of 1nhaler:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Nov 17, 2025	6940347	Seed	1756545	2076348	3146129	7313595
Nov 20, 2023	4507113	Seed	9725822	7665318	4286922	British Business Investments & 1 more
Mar 05, 2022	1965720	Seed	3517878	9708623	8847673	2858414

Access funding benchmarks and valuations. Sign up today!

View details of 1nhaler's funding rounds and investors

The founders of 1nhaler are Don Smith and Lisa McMyn. Lisa McMyn is the CEO of 1nhaler.

Here are the details of 1nhaler's key team members:

Don Smith: Co-Founder of 1nhaler.
Contact Info: 1 email address
Lisa McMyn: Co-Founder & CEO of 1nhaler.
Contact Info: 1 email address

View details of 1nhaler's Founder profiles and Board Members

1nhaler's employee count trend

1nhaler has 6 employees as of May 26. Here is 1nhaler's employee count trend over the years:

Uncover 1nhaler's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of 1nhaler include MannKind Corp, Impel NeuroPharma and Beyond Air. Here is the list of Top 10 competitors of 1nhaler, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	MannKind Corp 1991, Los Angeles (United States), Public	Developer of small-molecule drugs	$50M	Colt Ventures, Ignite 500 & 1 others	70/100
2nd	Impel NeuroPharma 2008, Seattle (United States), Public	Developer of an intranasal drug delivery technology for CNS diseases	$120M	VenBio, Norwest & 7 others	63/100
3rd	Beyond Air 2011, Garden City (United States), Public	Developer of therapeutics for multiple diseases	-	Collage Venture Partners, Cystic Fibrosis Foundation ... Read more	57/100
4th	Alexza 2000, Mountain View (United States), Public	Developer of products for the treatment of acute and intermittent conditions	$97M	Versant Ventures, Frazier Healthcare Partners ... & 16 others	57/100
5th	Qnovia 2018, Richmond (United States), Series B	Developer of inhaled drug delivery devices to deliver a broad range of pharmaceuticals	$50M	Blue Ledge Capital, Evolution VC Partners ... & 4 others	55/100
6th	Iconovo 2013, Lund (Sweden), Public	Develops inhalation devices	$3.56M	Smile Incubator, Eiffel Investment Group & 2 others	55/100
7th	OptiNose 2000, Morrisville (United States), Acquired	Developer of smart devices for nasal drug delivery	$120M	Avista Capital Partners, Fidelity Investments ... & 6 others	53/100
8th	NeOnc Technologies 2008, Los Angeles (United States), Public	Developer of drug delivery methods for pharma-based therapeutics	$18.7M	NIH, S3 Capital	52/100
9th	Nebu~Flow 2019, Glasgow (United Kingdom), Series A	Developer of aerosol delivery platform technology	$7.97M	Foresight Group, SCVC & 8 others	51/100
10th	Neurelis 2007, Encinitas (United States), Series D	Therapeutics for CNS disorders	$221M	HBM Healthcare Investments, LYZZ Capital & 4 others	51/100
13th	1nhaler 2017, Edinburgh (United Kingdom), Seed	Developer of single‑dose, disposable, dry‑powder inhaler for conditions like asthma, epilepsy, allergies, and Parkinsons	$4.74M	Scottish Enterprise, British Business Bank ... & 3 others	43/100